Chugai Pharmaceutical Co., Ltd. Share Price
Stocks
4519
JP3519400000
Pharmaceuticals
OTC Markets Traded|
Delayed
Japan Exchange
07:30:00 27/08/2026 BST
|
5-day change | 1st Jan Change | ||
| 6,947.00 JPY | -1.47% |
|
+0.90% | -15.72% |
| 08-21 | Alvotech Enters Licensing, Commercialization Deal for Two Biosimilars in US, Certain Asian Markets | MT |
| 08-18 | Chugai grants GSK exclusive global license for AID351 dengue antibody | AN |
| Market Cap | 11,601B 72.79B 62.48B 58.64B 53.56B 101B 6,943B 102B 694B 269B 3,503B 273B 267B | P/E 2026 * |
22.9x | P/E 2027 * | 19.8x |
|---|---|---|---|---|---|
| Enterprise Value | 10,691B 67.08B 57.58B 54.04B 49.36B 93.15B 6,398B 93.6B 640B 248B 3,228B 252B 246B | EV / Sales 2026 * |
7.7x | EV / Sales 2027 * | 6.83x |
| Free-Float |
38.12% | Yield 2026 * |
1.93% | Yield 2027 * | 2.2% |
Last Transcript : Chugai Pharmaceutical Co., Ltd.
| 1 day | -1.47% | ||
| 1 week | +0.90% | ||
| Current month | +0.22% | ||
| 1 month | +1.45% | ||
| 3 months | -8.42% | ||
| 6 months | -32.52% | ||
| Current year | -15.72% |
| 1 week | 6,902 |  | 7,141 |
| 1 month | 6,575 | | 7,229 |
| Current year | 6,575 | | 10,700 |
| 1 year | 6,153 | | 10,700 |
| 3 years | 4,197 | | 10,700 |
| 5 years | 3,191 | | 10,700 |
| 10 years | 1,003.33 | | 10,700 |
| Manager | Title | Age | Since |
|---|---|---|---|
Osamu Okuda
CEO | Chief Executive Officer | 63 | 28/02/2021 |
Iwaaki Taniguchi
DFI | Director of Finance/CFO | 59 | 27/03/2024 |
Kazuhiko Nishi
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Osamu Okuda
BRD | Director/Board Member | 63 | 29/02/2020 |
Iwaaki Taniguchi
BRD | Director/Board Member | 59 | 27/03/2024 |
| Director/Board Member | 51 | 28/02/2025 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.47% | +0.90% | +15.57% | +57.42% | 72.79B | |
| -3.59% | -7.10% | +61.60% | +114.83% | 1,060B | |
| -1.15% | -1.25% | +52.98% | +62.41% | 651B | |
| -1.09% | -1.15% | +26.18% | +79.22% | 465B | |
| -0.79% | +0.24% | +42.09% | +42.09% | 365B | |
| -0.78% | +0.05% | +25.57% | +41.75% | 300B | |
| -0.16% | +1.53% | +3.05% | +13.24% | 258B | |
| -0.43% | -0.46% | +52.06% | +71.75% | 238B | |
| -1.43% | +1.84% | -13.11% | -52.28% | 210B | |
| -0.46% | +0.33% | +29.05% | +92.67% | 184B | |
| Average | -1.13% | -0.36% | +29.51% | +52.31% | 380.32B | |
| Weighted average by Cap. | -1.63% | -2.07% | +39.93% | +67.77% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 1,388B 8.71B 7.48B 7.02B 6.41B 12.1B 831B 12.15B 83.05B 32.18B 419B 32.71B 32B | 1,529B 9.6B 8.24B 7.73B 7.06B 13.33B 915B 13.39B 91.49B 35.46B 462B 36.03B 35.25B |
| Net income | 507B 3.18B 2.73B 2.56B 2.34B 4.42B 303B 4.44B 30.32B 11.75B 153B 11.94B 11.68B | 585B 3.67B 3.15B 2.96B 2.7B 5.1B 350B 5.12B 35.02B 13.57B 177B 13.79B 13.49B |
| Net Debt | -910B -5.71B -4.9B -4.6B -4.2B -7.93B -545B -7.97B -54.44B -21.1B -275B -21.44B -20.98B | -1,151B -7.22B -6.2B -5.82B -5.31B -10.03B -689B -10.08B -68.84B -26.68B -347B -27.11B -26.52B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 27/08/26 | JP¥6,947.00 | -1.47% | 1,806,300 |
| 26/08/26 | JP¥7,051.00 | +1.45% | 1,503,700 |
| 25/08/26 | JP¥6,950.00 | -0.53% | 1,301,800 |
| 24/08/26 | JP¥6,987.00 | -0.34% | 1,196,300 |
| 21/08/26 | JP¥7,011.00 | -1.27% | 1,887,500 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- 4519 Stock
Select your edition
All financial news and data tailored to specific country editions
